The FTSE 100’s recent surge has been led by the pharmaceutical sector, marking a 13.7% increase in just the last month. Let’s delve into the standout performers that are leading the rally. AstraZeneca (AZN): +14.5% YTD AstraZeneca’s share price jumped higher following the release of a market-beating set of results… In the first quarter of 2024, AstraZeneca...
I'll keep accumulate under the support line. Whenever I sold AZN at resistance, I missed it and placed it back at the next support. Goes well till now.
Trying out my first elliot count. Also put a few rising wedges in there. I can't imagine the fundamentals that will bring AZN into such a deep correction though.
Analyzing the options chain and the chart patterns of AZN AstraZeneca PLC prior to the earnings report this week, I would consider purchasing the 66usd strike price in the money Puts with an expiration date of 2023-11-10, for a premium of approximately $2.30. If these options prove to be profitable prior to the earnings release, I would sell at least half of...
Daily Chart of AZN AZN bounced from an important support level. Waves 1 and 2 are complete. Wave 2 ended with a long pin bar. This means that the support level is strong. Volume has also picked up. AZN to go up to 75.
We are seeing an upward correction and have reached the MA and the top from 2 days ago again. The momentum is declining. That's clear - it is a correction. But as we are in a downtrend since August the preferred direction remains downward.
We are currently trading within a broader range. However, now we are approaching the important MA which is also the 50% retracement of the decline since August. As the window which had been opened on Monday has been closed now as well I can assume that the test of the high built on September 15th will fail. As this high was the 3rd lower high in a row since end of...
AstraZeneca's stock experienced a significant decline of over 4% on Monday due to uncertainties surrounding the future of CEO Pascal Soriot, as reported in the news. Initially, the company refrained from commenting on the report but later clarified that they do not engage in discussions regarding market rumors. Their shares, listed as NASDAQ: AZN, closed down...
The PEAD projected a bullish outlook for NASDAQ:AZN after a negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 85.71%.
The PEAD projected a bullish outlook for NASDAQ:AZN after a positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 80%.
The PEAD projected a bullish outlook for $AZN after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 83.33%.
AstraZeneca marginally eclipsed its prior cycle highs through the 72.00 level before pulling back to suggest a potential weekly double top pattern, however, I would highlight the lack of momentum divergence at this point, which suggests to me that the current retreat is corrective. On the four-hour time frame, we can clearly see an interim 5-wave sequence has been...
NASDAQ:AZN trading at an area of value. Looking forward to a breakout on the upside. NYSE:MRK has done well so far, need more healthcare stocks to catchup.
$AZN on 1HR Gap FIll Needed However it is in a downtrend right now. I am expecting a pullback. But Be careful of news catalysts. Potential pump off of that. What are your thoughts. Thanks, Kelly
AZN: The trend is still bullish in the long term but for the short term (1H) has a correction. Observe the money management . Follow, like, or request symbol analysis.
The PEAD projected a Neutral outlook for $AZN after a Negative Under reaction following its earnings release placing the stock in drift D with an expected accuracy of 66.67%.
AZN offers a good entry at the $60 level with a well calculated risk 1:3. The further discussion about the next vaccination, the upcoming winter and the oversold RSI should trigger the stock into profit pretty well.
The PEAD projected a Bullish outlook for $AZN after a Negative Under reaction following its earnings release placing the stock in drift D with an expected accuracy of 50%.